BioSyent logo.png
BioSyent Pharma to Introduce Gelclair® at AHNS 11th International Conference on Head and Neck Cancer
06. Juli 2023 17:53 ET | BioSyent Inc.
MISSISSAUGA, Ontario, July 06, 2023 (GLOBE NEWSWIRE) -- BioSyent Pharma Inc. (“BioSyent Pharma”), a subsidiary of BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX), is attending the...
BioSyent logo.png
BioSyent Announces Long-term Extension of Cathejell® Agreement
20. Juni 2023 08:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, June 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc....
BioSyent logo.png
BioSyent Announces Approval of New Product
31. Mai 2023 17:42 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received...
BioSyent logo.png
BioSyent Releases Financial Results for Q1 2023
26. Mai 2023 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 26, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2023. Key highlights...
BioSyent logo.png
BioSyent Declares Second Quarter 2023 Dividend
25. Mai 2023 17:40 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) --  BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent logo.png
BioSyent Schedules Q1 2023 Earnings Release for May 26, 2023
18. Mai 2023 08:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2023 on...
BioSyent logo.png
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians, Eight Years Running!
02. Mai 2023 14:59 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 02, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® is the #1 recommended iron supplement brand in Canada, based...
BioSyent logo.png
FeraMAXᴹᴰ est le 1er choix de supplément de fer recommandé par les pharmaciens et les médecins canadiens, pour la huitième année consécutive!
02. Mai 2023 14:59 ET | BioSyent Inc.
MISSISSAUGA, Ontario, 02 mai 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », Bourse de croissance TSX : RX) a le plaisir d’annoncer que FeraMAXMD est le 1er choix de marque de supplément de...
BioSyent logo.png
BioSyent to Present at 2023 Bloom Burton & Co. Healthcare Investor Conference
18. April 2023 09:15 ET | BioSyent Inc.
MISSISSAUGA, Ontario, April 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2023 Bloom Burton & Co....
BioSyent logo.png
BioSyent Announces Grant of Restricted Share Units
31. März 2023 17:42 ET | BioSyent Inc.
MISSISSAUGA, Ontario, March 31, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 72,020...